CKD Advisor
Developed by Dr. David Page, this is a clinical tool that advises on chronic kidney disease management. It is based on a combination of the UK NICE guidelines and the BC guidelines. For autopopulation to happen you will need to create the appropriate measurements and lab mapping or get help from your OSP to do this.
CKDAdvisor.html
—
HTML,
94Kb
File contents
<html>
<title>CKD Advisor</title>
<head>
<style type="text/css">
body
{
background-color:#b0c4de; width=900px;
}
</style>
<style type="text/css">
p.title{
text-transform: uppercase;
font-size: 16;
font-family: Arial;
font-weight: bolder;
text-align: left;
color: black;
}
p.heading{
font-size: 12;
font-family: Arial;
font-weight: bolder;
text-align: left;
vertical-align: top;
color: black;
}
p.normaltext{
font-size: 12;
font-family: Arial;
font-weight: normal;
text-align: left;
vertical-align: top;
color: black;
}
td.heading1{
font-size: 12;
font-family: Arial;
font-weight: bold;
text-align: left;
vertical-align: top;
color: white;
background-color:black ;
border-width: 1;
}
td.QuestionHeading{
font-size: 12;
font-family: Arial;
font-weight: bold;
text-align: left;
vertical-align: top;
color: white;
background-color: #404040;
border-width: 1;
}
td.AnswerHeading{
font-size: 12;
font-family: Arial;
font-weight: bold;
text-align: center;
vertical-align: top;
color: white;
background-color: #404040;
border-width: 1;
}
tr.odd{
background-color: #ffffff;
}
tr.even{
background-color: #8DB6CD;
}
td.question{
font-size: 12;
font-family: Arial;
font-weight: normal;
text-align: left;
vertical-align: top;
color: black;
border-width: 1;
}
td.question1{
font-size: 12;
font-family: Arial;
font-weight: normal;
text-align: center;
vertical-align: top;
color: black;
border-width: 1;
}
td.answer{
font-size: 12;
font-family: Arial;
font-weight: normal;
text-align: left;
vertical-align: middle;
color: black;
border-width: 1;
}
td.normaltext{
width: 100%;
font-size: 12;
font-family: Arial;
font-weight: normal;
text-align: left;
vertical-align: top;
color: black;
background-color: white;
border-width: 0;
}
input.formtext{
width: 100%;
height: 100%;
font-size: 12;
font-family: Arial;
font-weight: normal;
text-align: left;
vertical-align: top;
color: black;
background-color: white;
border-width: 1;
border-style: solid;
}
input.formtext2{
width: 100%;
height: 100%;
font-size: 9;
font-family: Arial;
font-weight: normal;
text-align: left;
vertical-align: top;
color: black;
background-color: #b0c4de;
border-width: 1;
border-style: solid;
}
input.formtext3{
width: 100%;
height: 100%;
font-size: 12;
font-family: Arial;
font-weight: normal;
text-align: left;
vertical-align: top;
color: black;
background-color:#D8D8D8 ;
border-width: 1;
border-style: solid;
}
textarea.formtext{
width: 100%;
height: auto;
font-size: 12;
font-family: Arial;
font-weight: normal;
text-align: left;
vertical-align: top;
color: black;
background-color: white;
border-width: 1;
border-style: solid;
}
</style>
<!-- CSS Script that removes textarea and textbox borders when printing ---(put this inbetween <header></header>)----------------->
<style type="text/css" media="print">
div.DoNotPrint {
display: none;
}
input.noborder {
border : 0px;
background: transparent;
}
textarea.noborder {
scrollbar-3dlight-color: transparent;
scrollbar-3dlight-color: transparent;
scrollbar-arrow-color: transparent;
scrollbar-base-color: transparent;
scrollbar-darkshadow-color: transparent;
scrollbar-face-color: transparent;
scrollbar-highlight-color: transparent;
scrollbar-shadow-color: transparent;
scrollbar-track-color: transparent;
background: transparent;
overflow: hidden;
//scrollbar : none;
border : 0px;
}
</style>
<!-- ----------------------------------------------------------------------------------------- -->
<!-------Script to optimize window on loading----------->
<script language="JavaScript">
top.window.moveTo(0,0);
if (document.all) {
top.window.resizeTo(screen.availWidth,screen.availHeight);
}
else if (document.layers||document.getElementById) {
if (top.window.outerHeight<screen.availHeight||top.window.outerWidth<screen.availWidth){
top.window.outerHeight = screen.availHeight;
top.window.outerWidth = 1050;
}
}
</script>
<script type="text/javascript" language="javascript">
function getCheckedValue(radioObj) {
if(!radioObj)
return parseInt(0);
var radioLength = radioObj.length;
if(radioLength == undefined)
if(radioObj.checked)
return parseInt(radioObj.value);
else
return parseInt(value);
for(var i = 0; i < radioLength; i++) {
if(radioObj[i].checked) {
return parseInt(radioObj[i].value);
}
}
return parseInt(0);
}
function start(){
passGender();
UpdateBP();
date();
totalScore();
}
function passGender()
{
if (document.getElementById("Sex").value == "M") {
document.getElementById("Male").checked = true;
}
else if (document.getElementById("Sex").value == "F") {
document.getElementById("Female").checked = true;
}
}
function UpdateBP(){
var ref=document.getElementById('BP').value.toString();
var mySplitResult = ref.split('/');
var x= mySplitResult[0];
document.getElementById('BP2').value = x;
return;
}
function date(){
var digital = new Date();
var days = digital.getDate();
var months = (digital.getMonth()*1 +1)*30.4;
var years = (digital.getFullYear())*365;
var dToday = days+months+years;
var myString1= document.getElementById("eGFR3").value;
if (myString1> "0"){
var mySplitResult1 = myString1.split("-");
var aBeGFR= mySplitResult1[0]*365;
var bBeGFR= mySplitResult1[1]*30.4;
var fBeGFR= mySplitResult1[2];
var gBeGFR= fBeGFR.split(" ");
var cBeGFR= gBeGFR[0];
var dBeGFR= (aBeGFR*1)+(bBeGFR*1)+(cBeGFR*1);
var eBeGFR= dToday - dBeGFR;
}
var myString2= document.getElementById("eGFR7").value;
if (myString2> "0"){
var mySplitResult2 = myString2.split("-");
var aeGFR= mySplitResult2[0]*365;
var beGFR= mySplitResult2[1]*30.4;
var feGFR= mySplitResult2[2];
var geGFR= feGFR.split(" ");
var ceGFR= geGFR[0];
var deGFR= (aeGFR*1)+(beGFR*1)+(ceGFR*1);
var eeGFR= dToday - deGFR;
}
var myString3= document.getElementById("BP3").value;
if (myString3> "0"){
var mySplitResult3 = myString3.split("-");
var aBP= mySplitResult3[0]*365;
var bBP= mySplitResult3[1]*30.4;
var fBP= mySplitResult3[2];
var gBP= fBP.split(" ");
var cBP= gBP[0];
var dBP= (aBP*1)+(bBP*1)+(cBP*1);
var eBP= dToday - dBP;
}
var myString4= document.getElementById("ACR3").value;
if (myString4> "0"){
var mySplitResult4 = myString4.split("-");
var aACR= mySplitResult4[0]*365;
var bACR= mySplitResult4[1]*30.4;
var fACR= mySplitResult4[2];
var gACR= fACR.split(" ");
var cACR= gACR[0];
var dACR= (aACR*1)+(bACR*1)+(cACR*1);
var eACR= dToday - dACR;
}
var myString5= document.getElementById("Alb3").value;
if (myString5> "0"){
var mySplitResult5 = myString5.split("-");
var aAlb= mySplitResult5[0]*365;
var bAlb= mySplitResult5[1]*30.4;
var fAlb= mySplitResult5[2];
var gAlb= fAlb.split(" ");
var cAlb= gAlb[0];
var dAlb= (aAlb*1)+(bAlb*1)+(cAlb*1);
var eAlb= (dToday - dAlb)/30;
}
var myString6= document.getElementById("Ca3").value;
if (myString6> "0"){
var mySplitResult6 = myString6.split("-");
var aCa= mySplitResult6[0]*365;
var bCa= mySplitResult6[1]*30.4;
var fCa= mySplitResult6[2];
var gCa= fCa.split(" ");
var cCa= gCa[0];
var dCa= (aCa*1)+(bCa*1)+(cCa*1);
var eCa= dToday - dCa;
}
var myString7= document.getElementById("PO43").value;
if (myString7> "0"){
var mySplitResult7 = myString7.split("-");
var aPO4= mySplitResult7[0]*365;
var bPO4= mySplitResult7[1]*30.4;
var fPO4= mySplitResult7[2];
var gPO4= fPO4.split(" ");
var cPO4= gPO4[0];
var dPO4= (aPO4*1)+(bPO4*1)+(cPO4*1);
var ePO4= dToday - dPO4;
}
var myString8= document.getElementById("iPTH3").value;
if (myString8> "0"){
var mySplitResult8 = myString8.split("-");
var aiPTH= mySplitResult8[0]*365;
var biPTH= mySplitResult8[1]*30.4;
var fiPTH= mySplitResult8[2];
var giPTH= fiPTH.split(" ");
var ciPTH= giPTH[0];
var diPTH= (aiPTH*1)+(biPTH*1)+(ciPTH*1);
var eiPTH= dToday - diPTH;
}
var myString9= document.getElementById("BMI3").value;
if (myString9> "0"){
var mySplitResult9 = myString9.split("-");
var aBMI= mySplitResult9[0]*365;
var bBMI= mySplitResult9[1]*30.4;
var fBMI= mySplitResult9[2];
var gBMI= fBMI.split(" ");
var cBMI= gBMI[0];
var dBMI= (aBMI*1)+(bBMI*1)+(cBMI*1);
var eBMI= dToday - dBMI;
}
var myString10= document.getElementById("Hb3").value;
if (myString10> "0"){
var mySplitResult10 = myString10.split("-");
var aHb= mySplitResult10[0]*365;
var bHb= mySplitResult10[1]*30.4;
var fHb= mySplitResult10[2];
var gHb= fHb.split(" ");
var cHb= gHb[0];
var dHb= (aHb*1)+(bHb*1)+(cHb*1);
var eHb= dToday - dHb;
}
var myString11= document.getElementById("TSAT3").value;
if (myString11> "0"){
var mySplitResult11 = myString11.split("-");
var aTSAT= mySplitResult11[0]*365;
var bTSAT= mySplitResult11[1]*30.4;
var fTSAT= mySplitResult11[2];
var gTSAT= fTSAT.split(" ");
var cTSAT= gTSAT[0];
var dTSAT= (aTSAT*1)+(bTSAT*1)+(cTSAT*1);
var eTSAT= dToday - dTSAT;
}
var myString12= document.getElementById("LDL3").value;
if (myString12> "0"){
var mySplitResult12 = myString12.split("-");
var aLDL= mySplitResult12[0]*365;
var bLDL= mySplitResult12[1]*30.4;
var fLDL= mySplitResult12[2];
var gLDL= fLDL.split(" ");
var cLDL= gLDL[0];
var dLDL= (aLDL*1)+(bLDL*1)+(cLDL*1);
var eLDL= dToday - dLDL;
}
var myString13= document.getElementById("A1C3").value;
if (myString13> "0"){
var mySplitResult13 = myString13.split("-");
var aA1C= mySplitResult13[0]*365;
var bA1C= mySplitResult13[1]*30.4;
var fA1C= mySplitResult13[2];
var gA1C= fA1C.split(" ");
var cA1C= gA1C[0];
var dA1C= (aA1C*1)+(bA1C*1)+(cA1C*1);
var eA1C= dToday - dA1C;
}
//stage 0,1,2 eGFR ACR BP BMI Q 12 months, rest gray
if ( (eeGFR > 365)&&(document.getElementById("eGFR5").value >59)){
document.getElementById("eGFR7").style.background='#C6B5DE';
}
if ( (eeGFR > 335)&&(eeGFR < 366)&&(document.getElementById("eGFR5").value >59)){
document.getElementById("eGFR7").style.background='#FFA07A';
}
if ( (eeGFR < 336)&&(eeGFR >= 0)&&(document.getElementById("eGFR5").value >59)){
document.getElementById("eGFR7").style.background='#9AFF9A';
}
if ( (eACR >365)&&(document.getElementById("eGFR5").value >59)){
document.getElementById("ACR3").style.background='#C6B5DE';
}
if ( (eACR > 335)&&(eACR < 366)&&(document.getElementById("eGFR5").value >59)){
document.getElementById("ACR3").style.background='#FFA07A';
}
if ( (eACR< 336)&&(eACR >= 0)&&(document.getElementById("eGFR5").value >59)){
document.getElementById("ACR3").style.background='#9AFF9A';
}
if ( (eACR== null)&&(document.getElementById("eGFR5").value >59)){
document.getElementById("ACR3").style.background='#C6B5DE';
document.getElementById("ACR2").style.background='#C6B5DE';
}
if ( (eBP >365)&&(document.getElementById("eGFR5").value >59)){
document.getElementById("BP3").style.background='#C6B5DE';
}
if ( (eBP > 335)&&(eBP < 366)&&(document.getElementById("eGFR5").value >59)){
document.getElementById("BP3").style.background='#FFA07A';
}
if ( (eBP< 336)&&(eBP >= 0)&&(document.getElementById("eGFR5").value >59)){
document.getElementById("BP3").style.background='#9AFF9A';
}
if ( (eBP== null)&&(document.getElementById("eGFR5").value >59)){
document.getElementById("BP3").style.background='#C6B5DE';
document.getElementById("BP2").style.background='#C6B5DE';
}
if (eBMI >365){
document.getElementById("BMI3").style.background='#C6B5DE';
}
if ( (eBMI > 335)&&(eBMI< 366)){
document.getElementById("BMI3").style.background='#FFA07A';
}
if ( (eBMI< 336)&&(eBMI >= 0)){
document.getElementById("BMI3").style.background='#9AFF9A';
}
if ( (eBMI== null)){
document.getElementById("BMI3").style.background='#C6B5DE';
document.getElementById("BMI2").style.background='#C6B5DE';
}
if (document.getElementById("eGFR5").value >59){
document.getElementById("Alb3").style.background='#D8D8D8';
document.getElementById("Ca3").style.background='#D8D8D8';
document.getElementById("PO43").style.background='#D8D8D8';
document.getElementById("TSAT3").style.background='#D8D8D8';
document.getElementById("iPTH3").style.background='#D8D8D8';
document.getElementById("A1C3").style.background='#D8D8D8';
document.getElementById("Hb3").style.background='#D8D8D8';
document.getElementById("eGFR3").style.background='#D8D8D8';
document.getElementById("LDL3").style.background='#D8D8D8';
document.getElementById("Alb2").style.background='#D8D8D8';
document.getElementById("Ca2").style.background='#D8D8D8';
document.getElementById("PO42").style.background='#D8D8D8';
document.getElementById("TSAT2").style.background='#D8D8D8';
document.getElementById("iPTH2").style.background='#D8D8D8';
document.getElementById("A1C2").style.background='#D8D8D8';
document.getElementById("Hb2").style.background='#D8D8D8';
document.getElementById("eGFR2").style.background='#D8D8D8';
document.getElementById("LDL2").style.background='#D8D8D8';
}
//stage 3 eGFR,ACR,BP Q6month
if ( (eeGFR > 183)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >29)){
document.getElementById("eGFR7").style.background='#C6B5DE';
}
if ( (eeGFR > 153)&&(eeGFR < 184)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >29)){
document.getElementById("eGFR7").style.background='#FFA07A';
}
if ( (eeGFR < 154)&&(eeGFR >= 0)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >29)){
document.getElementById("eGFR7").style.background='#9AFF9A';
}
if ( (eACR >183)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >29)){
document.getElementById("ACR3").style.background='#C6B5DE';
}
if ( (eACR > 153)&&(eACR < 184)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >29)){
document.getElementById("ACR3").style.background='#FFA07A';
}
if ( (eACR< 154)&&(eACR >= 0)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >29)){
document.getElementById("ACR3").style.background='#9AFF9A';
}
if ( (eACR== null)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >29)){
document.getElementById("ACR3").style.background='#C6B5DE';
document.getElementById("ACR2").style.background='#C6B5DE';
}
if ( (eBP >183)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >29)){
document.getElementById("BP3").style.background='#C6B5DE';
}
if ( (eBP > 153)&&(eBP < 184)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >29)){
document.getElementById("BP3").style.background='#FFA07A';
}
if ( (eBP< 154)&&(eBP >= 0)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >29)){
document.getElementById("BP3").style.background='#9AFF9A';
}
if ( (eBP== null)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >29)){
document.getElementById("BP3").style.background='#C6B5DE';
document.getElementById("BP2").style.background='#C6B5DE';
}
//Stage 4 eGFR,ACR,BP Q3month
if ( (eeGFR > 91)&&(document.getElementById("eGFR5").value <30)&&(document.getElementById("eGFR5").value >14)){
document.getElementById("eGFR7").style.background='#C6B5DE';
}
if ( (eeGFR > 61)&&(eeGFR < 92)&&(document.getElementById("eGFR5").value <30)&&(document.getElementById("eGFR5").value >14)){
document.getElementById("eGFR7").style.background='#FFA07A';
}
if ( (eeGFR < 62)&&(eeGFR >= 0)&&(document.getElementById("eGFR5").value <30)&&(document.getElementById("eGFR5").value >14)){
document.getElementById("eGFR7").style.background='#9AFF9A';
}
if ( (eACR >91)&&(document.getElementById("eGFR5").value <30)&&(document.getElementById("eGFR5").value >14)){
document.getElementById("ACR3").style.background='#C6B5DE';
}
if ( (eACR > 61)&&(eACR < 92)&&(document.getElementById("eGFR5").value <30)&&(document.getElementById("eGFR5").value >14)){
document.getElementById("ACR3").style.background='#FFA07A';
}
if ( (eACR< 62)&&(eACR >= 0)&&(document.getElementById("eGFR5").value <30)&&(document.getElementById("eGFR5").value >14)){
document.getElementById("ACR3").style.background='#9AFF9A';
}
if ( (eACR== null)&&(document.getElementById("eGFR5").value <30)&&(document.getElementById("eGFR5").value >14)){
document.getElementById("ACR3").style.background='#C6B5DE';
document.getElementById("ACR2").style.background='#C6B5DE';
}
if ( (eBP >91)&&(document.getElementById("eGFR5").value <30)&&(document.getElementById("eGFR5").value >14)){
document.getElementById("BP3").style.background='#C6B5DE';
}
if ( (eBP > 61)&&(eBP < 92)&&(document.getElementById("eGFR5").value <30)&&(document.getElementById("eGFR5").value >14)){
document.getElementById("BP3").style.background='#FFA07A';
}
if ( (eBP< 62)&&(eBP >= 0)&&(document.getElementById("eGFR5").value <30)&&(document.getElementById("eGFR5").value >14)){
document.getElementById("BP3").style.background='#9AFF9A';
}
if ( (eBP== null)&&(document.getElementById("eGFR5").value <30)&&(document.getElementById("eGFR5").value >14)){
document.getElementById("BP3").style.background='#C6B5DE';
document.getElementById("BP2").style.background='#C6B5DE';
}
//Stage 5 eGFR,ACR,BP Q6weeks
if ( (eeGFR > 42)&&(document.getElementById("eGFR5").value <15)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("eGFR7").style.background='#C6B5DE';
}
if ( (eeGFR > 28)&&(eeGFR < 43)&&(document.getElementById("eGFR5").value <15)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("eGFR7").style.background='#FFA07A';
}
if ( (eeGFR < 29)&&(eeGFR >= 0)&&(document.getElementById("eGFR5").value <15)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("eGFR7").style.background='#9AFF9A';
}
if ( (eACR > 42)&&(document.getElementById("eGFR5").value <15)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("ACR3").style.background='#C6B5DE';
}
if ( (eACR > 28)&&(eACR < 43)&&(document.getElementById("eGFR5").value <15)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("ACR3").style.background='#FFA07A';
}
if ( (eACR < 29)&&(eACR >= 0)&&(document.getElementById("eGFR5").value <15)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("ACR3").style.background='#9AFF9A';
}
if ( (eACR== null)&&(document.getElementById("eGFR5").value <15)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("ACR3").style.background='#C6B5DE';
document.getElementById("ACR2").style.background='#C6B5DE';
}
if ( (eBP > 42)&&(document.getElementById("eGFR5").value <15)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("BP3").style.background='#C6B5DE';
}
if ( (eBP > 28)&&(eBP < 43)&&(document.getElementById("eGFR5").value <15)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("BP3").style.background='#FFA07A';
}
if ( (eBP < 29)&&(eBP >= 0)&&(document.getElementById("eGFR5").value <15)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("BP3").style.background='#9AFF9A';
}
if ( (eBP== null)&&(document.getElementById("eGFR5").value <15)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("BP3").style.background='#C6B5DE';
document.getElementById("BP2").style.background='#C6B5DE';
}
//Stage 3,4,5 metabolic tests Q12 months
if ((eAlb >365)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("Alb3").style.background='#C6B5DE';
}
if ( (eAlb > 335)&&(eAlb< 366)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("Alb3").style.background='#FFA07A';
}
if ( (eAlb< 336)&&(eAlb >= 0)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("Alb3").style.background='#9AFF9A';
}
if ( (eAlb== null)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("Alb3").style.background='#C6B5DE';
document.getElementById("Alb2").style.background='#C6B5DE';
}
if ((eHb >365)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("Hb3").style.background='#C6B5DE';
}
if ( (eHb > 335)&&(eHb< 366)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("Hb3").style.background='#FFA07A';
}
if ( (eHb< 336)&&(eHb >= 0)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("Hb3").style.background='#9AFF9A';
}
if ( (eHb== null)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("Hb3").style.background='#C6B5DE';
document.getElementById("Hb2").style.background='#C6B5DE';
}
if ((eCa >365)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("Ca3").style.background='#C6B5DE';
}
if ( (eCa > 335)&&(eCa< 366)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("Ca3").style.background='#FFA07A';
}
if ( (eCa< 336)&&(eCa >= 0)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("Ca3").style.background='#9AFF9A';
}
if ( (eCa== null)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("Ca3").style.background='#C6B5DE';
document.getElementById("Ca2").style.background='#C6B5DE';
}
if ((eTSAT >365)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("TSAT3").style.background='#C6B5DE';
}
if ( (eTSAT > 335)&&(eTSAT< 366)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("TSAT3").style.background='#FFA07A';
}
if ( (eTSAT< 336)&&(eTSAT >= 0)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("TSAT3").style.background='#9AFF9A';
}
if ( (eTSAT== null)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("TSAT3").style.background='#C6B5DE';
document.getElementById("TSAT2").style.background='#C6B5DE';
}
if ((ePO4 >365)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("PO43").style.background='#C6B5DE';
}
if ( (ePO4 > 335)&&(ePO4< 366)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("PO43").style.background='#FFA07A';
}
if ( (ePO4< 336)&&(ePO4 >= 0)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("PO43").style.background='#9AFF9A';
}
if ( (ePO4== null)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("PO43").style.background='#C6B5DE';
document.getElementById("PO42").style.background='#C6B5DE';
}
if ((eLDL >365)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("LDL3").style.background='#C6B5DE';
}
if ( (eLDL > 335)&&(eLDL< 366)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("LDL3").style.background='#FFA07A';
}
if ( (eLDL< 336)&&(eLDL >= 0)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("LDL3").style.background='#9AFF9A';
}
if ( (eLDL== null)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("LDL3").style.background='#C6B5DE';
document.getElementById("LDL2").style.background='#C6B5DE';
}
if ((eiPTH >365)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("iPTH3").style.background='#C6B5DE';
}
if ( (eiPTH > 335)&&(eiPTH< 366)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("iPTH3").style.background='#FFA07A';
}
if ( (eiPTH< 336)&&(eiPTH >= 0)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("iPTH3").style.background='#9AFF9A';
}
if ( (eiPTH== null)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("iPTH3").style.background='#C6B5DE';
document.getElementById("iPTH2").style.background='#C6B5DE';
}
if ((eA1C >365)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("A1C3").style.background='#C6B5DE';
}
if ( (eA1C > 335)&&(eA1C< 366)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("A1C3").style.background='#FFA07A';
}
if ( (eA1C< 336)&&(eA1C >= 0)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("A1C3").style.background='#9AFF9A';
}
if ( (eA1C== null)&&(document.getElementById("eGFR5").value <60)&&(document.getElementById("eGFR5").value >0)){
document.getElementById("A1C3").style.background='#C6B5DE';
document.getElementById("A1C2").style.background='#C6B5DE';
}
}
function totalScore(){
var j = 0;
j += getCheckedValue(document.FormName.GenderRadio);
if (document.getElementById ("A1C2").value > 6.2){
document.getElementById("E1").checked = true;
}
if (document.getElementById ("BP2").value > 140){
document.getElementById("E2").checked = true;
}
if (document.getElementById ("eGFR5").value == "> 120") {
document.getElementById("eGFR5").style.background='#3CB371';
}
if (document.getElementById ("eGFR5").value > 89) {
document.getElementById("eGFR5").style.background='#3CB371';
}
if ((document.getElementById ("eGFR5").value > 59)&& (document.getElementById ("eGFR5").value <90)) {
document.getElementById("eGFR5").style.background='#ADEAEA';
}
if ((document.getElementById ("eGFR5").value > 29)&& (document.getElementById ("eGFR5").value <60)){
document.getElementById("eGFR5").style.background='#00CCFF';
}
if ((document.getElementById ("eGFR5").value > 14)&& (document.getElementById ("eGFR5").value <30)){
document.getElementById("eGFR5").style.background='#0066FF';
}
if ((document.getElementById ("eGFR5").value > 0)&& (document.getElementById ("eGFR5").value <15)){
document.getElementById("eGFR5").style.background='#0033FF';
}
if ( (document.getElementById("ET1").checked)||(document.getElementById("ET2").checked)||(document.getElementById("E1").checked)||(document.getElementById("E2").checked)||(document.getElementById("E3").checked)||(document.getElementById("E4").checked)||(document.getElementById("E6").checked)||(document.getElementById("E7").checked)||(document.getElementById ("A1C2").value > 6.2)){
document.getElementById("0").style.background='yellow';
}
if (document.getElementById("E1").checked){
document.getElementById("lifestyle").style.background='yellow';
document.getElementById("RDM").style.background='yellow';
}
if (document.getElementById("E2").checked){
document.getElementById("lifestyle").style.background='yellow';
document.getElementById("RHBP").style.background='yellow';
}
if ((document.getElementById ("eGFR5").value > 89)&& (document.getElementById("E3").checked)) {
document.getElementById("0").style.background='#8DB6CD';
document.getElementById("1").style.background='yellow';
document.getElementById("2").style.background='#8DB6CD';
document.getElementById("3").style.background='#8DB6CD';
document.getElementById("4").style.background='#8DB6CD';
document.getElementById("5").style.background='#8DB6CD';
}
if ((document.getElementById ("eGFR5").value > 89)&& (document.getElementById("E6").checked)) {
document.getElementById("0").style.background='#8DB6CD';
document.getElementById("1").style.background='yellow';
document.getElementById("2").style.background='#8DB6CD';
document.getElementById("3").style.background='#8DB6CD';
document.getElementById("4").style.background='#8DB6CD';
document.getElementById("5").style.background='#8DB6CD';
}
if ((document.getElementById ("eGFR5").value > 89)&& (document.getElementById ("ACR2").value > 29)) {
document.getElementById("0").style.background='#8DB6CD';
document.getElementById("1").style.background='yellow';
document.getElementById("2").style.background='#8DB6CD';
document.getElementById("3").style.background='#8DB6CD';
document.getElementById("4").style.background='#8DB6CD';
document.getElementById("5").style.background='#8DB6CD';
}
if ((document.getElementById ("eGFR5").value > 89)&& (document.getElementById ("ACR2").value > 2.5)&& (document.getElementById("E1").checked)) {
document.getElementById("0").style.background='#8DB6CD';
document.getElementById("1").style.background='yellow';
document.getElementById("2").style.background='#8DB6CD';
document.getElementById("3").style.background='#8DB6CD';
document.getElementById("4").style.background='#8DB6CD';
document.getElementById("5").style.background='#8DB6CD';
}
if ((document.getElementById ("eGFR5").value > 59)&& (document.getElementById ("eGFR5").value <90)&& (document.getElementById("E3").checked)){
document.getElementById("0").style.background='#8DB6CD';
document.getElementById("1").style.background='#8DB6CD';
document.getElementById("2").style.background='yellow';
document.getElementById("3").style.background='#8DB6CD';
document.getElementById("4").style.background='#8DB6CD';
document.getElementById("5").style.background='#8DB6CD';
}
if ((document.getElementById ("eGFR5").value > 59)&& (document.getElementById ("eGFR5").value <90)&& (document.getElementById ("ACR2").value > 29)){
document.getElementById("0").style.background='#8DB6CD';
document.getElementById("1").style.background='#8DB6CD';
document.getElementById("2").style.background='yellow';
document.getElementById("3").style.background='#8DB6CD';
document.getElementById("4").style.background='#8DB6CD';
document.getElementById("5").style.background='#8DB6CD';
}
if ((document.getElementById ("eGFR5").value > 59)&& (document.getElementById ("eGFR5").value <90)&& (document.getElementById ("ACR2").value > 2.5)&& (document.getElementById("E3").checked)){
document.getElementById("0").style.background='#8DB6CD';
document.getElementById("1").style.background='#8DB6CD';
document.getElementById("2").style.background='yellow';
document.getElementById("3").style.background='#8DB6CD';
document.getElementById("4").style.background='#8DB6CD';
document.getElementById("5").style.background='#8DB6CD';
}
if ((document.getElementById ("eGFR5").value > 59)&& (document.getElementById ("eGFR5").value <90)&& (document.getElementById("E6").checked)){
document.getElementById("0").style.background='#8DB6CD';
document.getElementById("1").style.background='#8DB6CD';
document.getElementById("2").style.background='yellow';
document.getElementById("3").style.background='#8DB6CD';
document.getElementById("4").style.background='#8DB6CD';
document.getElementById("5").style.background='#8DB6CD';
}
if ((document.getElementById ("eGFR5").value > 29)&& (document.getElementById ("eGFR5").value <60)){
document.getElementById("0").style.background='#8DB6CD';
document.getElementById("1").style.background='#8DB6CD';
document.getElementById("2").style.background='#8DB6CD';
document.getElementById("3").style.background='yellow';
document.getElementById("4").style.background='#8DB6CD';
document.getElementById("5").style.background='#8DB6CD';
}
if ((document.getElementById ("eGFR5").value > 14)&& (document.getElementById ("eGFR5").value <30)){
document.getElementById("0").style.background='#8DB6CD';
document.getElementById("1").style.background='#8DB6CD';
document.getElementById("2").style.background='#8DB6CD';
document.getElementById("3").style.background='#8DB6CD';
document.getElementById("4").style.background='yellow';
document.getElementById("5").style.background='#8DB6CD';
}
if ((document.getElementById ("eGFR5").value > 0)&& (document.getElementById ("eGFR5").value <15)){
document.getElementById("0").style.background='#8DB6CD';
document.getElementById("1").style.background='#8DB6CD';
document.getElementById("2").style.background='#8DB6CD';
document.getElementById("3").style.background='#8DB6CD';
document.getElementById("4").style.background='#8DB6CD';
document.getElementById("5").style.background='yellow';
}
if ((document.getElementById ("iPTH2").value > 0)&& (document.getElementById ("iPTH2").value < 7.7)){
document.getElementById("iPTH2").style.background='#00BFFF';
}
if ((document.getElementById ("iPTH2").value > 3.78)&& (document.getElementById ("iPTH2").value < 7.71)){
document.getElementById("iPTH2").style.background='#3CB371';
}
if (document.getElementById ("iPTH2").value > 7.7){
document.getElementById("iPTH2").style.background='#CC3333';
}
if ((document.getElementById ("eGFR5").value > 59)&& (document.getElementById ("iPTH2").value > 7.7)){
document.getElementById("MD").style.background='yellow';
document.getElementById("MS3").style.background='#8DB6CD';
document.getElementById("MS4").style.background='#8DB6CD';
document.getElementById("MS5").style.background='#8DB6CD';
}
if ((document.getElementById ("eGFR5").value > 29)&& (document.getElementById ("eGFR5").value <60) && (document.getElementById ("iPTH2").value > 7.7)){
document.getElementById("MD").style.background='yellow';
document.getElementById("MS3").style.background='yellow';
document.getElementById("MS4").style.background='#8DB6CD';
document.getElementById("MS5").style.background='#8DB6CD';
}
if ((document.getElementById ("eGFR5").value > 14)&& (document.getElementById ("eGFR5").value <30) && (document.getElementById ("iPTH2").value > 12)){
document.getElementById("MD").style.background='yellow';
document.getElementById("MS3").style.background='#8DB6CD';
document.getElementById("MS4").style.background='yellow';
document.getElementById("MS5").style.background='#8DB6CD';
}
if ((document.getElementById ("eGFR5").value < 15) && (document.getElementById ("iPTH2").value > 33)){
document.getElementById("MD").style.background='yellow';
document.getElementById("MS3").style.background='#8DB6CD';
document.getElementById("MS4").style.background='#8DB6CD';
document.getElementById("MS5").style.background='yellow';
}
if ((document.getElementById ("iPTH2").value >7.6)&&(document.getElementById ("iPTH2").value <12.1) && (document.getElementById ("eGFR5").value >14)&& (document.getElementById ("eGFR5").value <30)){
document.getElementById("iPTH2").style.background='#348017';
}
if ((document.getElementById ("iPTH2").value >7.6)&&(document.getElementById ("iPTH2").value <33.1) && (document.getElementById ("eGFR5").value <15)&& (document.getElementById ("eGFR5").value > 0)){
document.getElementById("iPTH2").style.background='#348017';
}
if ((document.getElementById ("eGFR5").value > 0)&& (document.getElementById ("eGFR5").value <30)){
document.getElementById("refer").style.background='yellow';
document.getElementById("refer1").style.background='yellow';
}
if (document.getElementById ("ACR2").value > 29){
document.getElementById("ACR2").style.background='#CC3333';
}
if ((document.getElementById ("ACR2").value <30)&& (document.getElementById ("ACR2").value > 0)){
document.getElementById("ACR2").style.background='#3CB371';
}
if ((document.getElementById ("ACR2").value == "< 1.7")){
document.getElementById("ACR2").style.background='#3CB371';
}
if (document.getElementById ("ACR2").value > 69){
document.getElementById("refer").style.background='yellow';
document.getElementById("refer2").style.background='yellow';
}
if ((document.getElementById ("ACR2").value > 29) && (document.getElementById("E6").checked)){
document.getElementById("refer").style.background='yellow';
document.getElementById("refer3").style.background='yellow';
}
if ((document.getElementById ("ACR2").value > 1.99) && (j==1)&& (document.getElementById("E1").checked) ){
document.getElementById("ACE").style.background='yellow';
document.getElementById("DMACR").style.background='yellow';
document.getElementById("ACR2").style.background='#CC3333';
}
if ((document.getElementById ("ACR2").value > 2.79) && (j==2)&& (document.getElementById("E1").checked) ){
document.getElementById("ACE").style.background='yellow';
document.getElementById("DMACR").style.background='yellow';
document.getElementById("ACR2").style.background='#CC3333';
}
if ((document.getElementById ("ACR2").value > 29)&& (document.getElementById("E2").checked)){
document.getElementById("ACE").style.background='yellow';
document.getElementById("HBPACR").style.background='yellow';
}
if (document.getElementById ("ACR2").value > 69){
document.getElementById("ACE").style.background='yellow';
document.getElementById("NACR").style.background='yellow';
}
if ((document.getElementById ("eGFR2").value - document.getElementById ("eGFR5").value) >9){
document.getElementById("refer").style.background='yellow';
document.getElementById("refer4").style.background='yellow';
document.getElementById("eGFR2").style.background='#F87217';
}
if ((document.getElementById ("BP2").value < 141)&& (document.getElementById ("BP2").value > 0)){
document.getElementById("BP2").style.background='#3CB371';
}
if (document.getElementById ("BP2").value > 140){
document.getElementById("BP2").style.background='#CC3333';
document.getElementById("MBP").style.background='yellow';
document.getElementById("minus").style.background='yellow';
document.getElementById("plus").style.background='#8DB6CD';
}
if ((document.getElementById ("BP2").value > 130)&&((document.getElementById ("ACR2").value > 29)||(document.getElementById("E1").checked))){
document.getElementById("BP2").style.background='#CC3333';
document.getElementById("MBP").style.background='yellow';
document.getElementById("minus").style.background='#8DB6CD';
document.getElementById("plus").style.background='yellow';
}
if ((document.getElementById ("eGFR5").value > 0)&& (document.getElementById ("eGFR5").value <30)){
document.getElementById("US").style.background='yellow';
document.getElementById("US1").style.background='yellow';
}
if (document.getElementById("E7").checked){
document.getElementById("US").style.background='yellow';
document.getElementById("US2").style.background='yellow';
}
if (document.getElementById("E6").checked){
document.getElementById("US").style.background='yellow';
document.getElementById("US3").style.background='yellow';
}
if ((document.getElementById ("eGFR2").value - document.getElementById ("eGFR5").value) >9){
document.getElementById("US").style.background='yellow';
document.getElementById("US4").style.background='yellow';
}
if ((document.getElementById ("TSAT2").value < 0.20)&& (document.getElementById ("TSAT2").value > 0)){
document.getElementById("MFe").style.background='yellow';
document.getElementById("TSAT0.2").style.background='yellow';
}
if ((document.getElementById ("Hb2").value < 110)&& (document.getElementById ("Hb2").value > 0)){
document.getElementById("MFe").style.background='yellow';
document.getElementById("Hb110").style.background='yellow';
}
if ((document.getElementById ("Hb2").value > 180)&& (j==1)){
document.getElementById("Hb2").style.background='#CC3333';
}
if ((document.getElementById ("Hb2").value < 135)&& (j==1)&& (document.getElementById ("Hb2").value > 0)) {
document.getElementById("Hb2").style.background='#00BFFF';
}
if ((document.getElementById ("Hb2").value > 134)&& (j==1)&& (document.getElementById ("Hb2").value < 181)) {
document.getElementById("Hb2").style.background='#3CB371';
}
if ((document.getElementById ("Hb2").value > 160)&& (j==2)){
document.getElementById("Hb2").style.background='#CC3333';
}
if ((document.getElementById ("Hb2").value < 115)&& (j==2)&& (document.getElementById ("Hb2").value > 0)) {
document.getElementById("Hb2").style.background='#00BFFF';
}
if ((document.getElementById ("Hb2").value > 114)&& (j==2)&& (document.getElementById ("Hb2").value < 161)) {
document.getElementById("Hb2").style.background='#3CB371';
}
if ((document.getElementById ("BMI2").value < 25.1)&& (document.getElementById ("BMI2").value > 18.4)){
document.getElementById("BMI2").style.background='#3CB371';
}
if ((document.getElementById ("BMI2").value < 18.5)&& (document.getElementById ("BMI2").value > 0)){
document.getElementById("BMI2").style.background='#00BFFF';
}
if ((document.getElementById ("BMI2").value < 30)&& (document.getElementById ("BMI2").value > 25)){
document.getElementById("BMI2").style.background='#348017';
document.getElementById("lifestyle").style.background='yellow';
document.getElementById("RBMI").style.background='yellow';
}
if (document.getElementById ("BMI2").value > 29){
document.getElementById("lifestyle").style.background='yellow';
document.getElementById("BMI2").style.background='#CC3333';
document.getElementById("RBMI").style.background='yellow';
}
if ((document.getElementById ("A1C2").value < 4.6)&& (document.getElementById ("A1C2").value > 0)){
document.getElementById("A1C2").style.background='#00BFFF';
}
if ((document.getElementById ("A1C2").value < 6.21)&& (document.getElementById ("A1C2").value > 4.59)){
document.getElementById("A1C2").style.background='#3CB371';
}
if (document.getElementById ("A1C2").value > 6.2){
document.getElementById("A1C2").style.background='#CC3333';
}
if ((document.getElementById ("LDL2").value < 1.5)&& (document.getElementById ("LDL2").value > 0)){
document.getElementById("LDL2").style.background='#00BFFF';
}
if ((document.getElementById ("LDL2").value < 3.5)&& (document.getElementById ("LDL2").value > 1.4)){
document.getElementById("LDL2").style.background='#3CB371';
}
if (document.getElementById ("LDL2").value > 3.4){
document.getElementById("LDL2").style.background='#CC3333';
}
if ((document.getElementById ("LDL2").value > 2.0)&& (document.getElementById("E1").checked)){
document.getElementById("LDL2").style.background='#CC3333';
}
if (document.getElementById ("LDL2").value > 2.4){
document.getElementById("lifestyle").style.background='yellow';
document.getElementById("RLDL").style.background='yellow';
document.getElementById("statin").style.background='yellow';
}
if (document.getElementById ("Alb2").value > 50){
document.getElementById("Alb2").style.background='#CC3333';
}
if ((document.getElementById ("Alb2").value > 34.9)&& (document.getElementById ("Alb2").value < 50.1)){
document.getElementById("Alb2").style.background='#3CB371';
}
if ((document.getElementById ("Alb2").value > 0)&& (document.getElementById ("Alb2").value < 35)){
document.getElementById("Alb2").style.background='#00BFFF';
}
if (document.getElementById ("Ca2").value > 2.6){
document.getElementById("Ca2").style.background='#CC3333';
}
if ((document.getElementById ("Ca2").value > 2.09)&& (document.getElementById ("Ca2").value < 2.61)){
document.getElementById("Ca2").style.background='#3CB371';
}
if ((document.getElementById ("Ca2").value > 0)&& (document.getElementById ("Ca2").value < 2.1)){
document.getElementById("Ca2").style.background='#00BFFF';
document.getElementById("CaValue").style.background='yellow';
document.getElementById("MCa").style.background='yellow';
document.getElementById("MD").style.background='yellow';
}
if (document.getElementById ("PO42").value > 1.8){
document.getElementById("PO42").style.background='#CC3333';
}
if (document.getElementById ("PO42").value > 1.5){
document.getElementById("PO4Value").style.background='yellow';
}
if ((document.getElementById ("PO42").value > 0.79)&& (document.getElementById ("PO42").value < 1.51)){
document.getElementById("PO42").style.background='#3CB371';
}
if ((document.getElementById ("PO42").value > 1.5)&& (document.getElementById ("PO42").value < 1.81)){
document.getElementById("PO42").style.background='#348017';
}
if ((document.getElementById ("PO42").value > 0)&& (document.getElementById ("PO42").value < 0.8)){
document.getElementById("PO42").style.background='#00BFFF';
}
if (document.getElementById ("PO42").value > 1.5){
document.getElementById("MCa").style.background='yellow';
document.getElementById("MPO4").style.background='yellow';
document.getElementById("PO4Value").style.background='yellow';
document.getElementById("PO41.5").style.background='yellow';
}
if (document.getElementById ("TSAT2").value > 0.54){
document.getElementById("TSAT2").style.background='#CC3333';
}
if ((document.getElementById ("TSAT2").value > 0.45)&& (document.getElementById ("TSAT2").value < 0.55)){
document.getElementById("TSAT2").style.background='#348017';
}
if (document.getElementById ("TSAT2").value > 0.45){
document.getElementById("FeOverload").style.background='yellow';
document.getElementById("TsatValue").style.background='yellow';
}
if ((document.getElementById ("TSAT2").value > 0.19)&& (document.getElementById ("TSAT2").value < 0.46)){
document.getElementById("TSAT2").style.background='#3CB371';
}
if ((document.getElementById ("TSAT2").value > 0.14)&& (document.getElementById ("TSAT2").value < 0.2)){
document.getElementById("TSAT2").style.background='#348017';
}
if ((document.getElementById ("TSAT2").value > 0)&& (document.getElementById ("TSAT2").value < 0.15)){
document.getElementById("TSAT2").style.background='#00BFFF';
}
}
</script>
</head>
<body onload="start();">
<form method="post" action="" name="FormName">
<input name="BP" id="BP" type="hidden" oscarDB=m$BP#value>
<div name="demographics" >
<p class="title">
CKD Advisor</p>
The aim is to identify patients at risk of progressive renal disease an reduce associated risks.
<tr>
<li><a href="http://guidance.nice.org.uk/CG73" target="_blank">NICE CKD Guidelines</a> <a href="http://www.renal.org/whatwedo/InformationResources/CKDeGUIDE.aspx" target="_blank">UK eCKD Guidelines</a></li><li><a href="http://www.kidney.org/professionals/kdoqi/guidelines_ckd/toc.htm" target="_blank">KDOQI CKD Guidelines</a> <a href="http://www.danielyoung.net/docs/iPTH&Ergo.pdf" target="_blank">KDOQI CKD Highlight summary</a></li><li><a href="http://www.bcguidelines.ca/gpac/pdf/ckd.pdf" target="_blank">BC CKD Guidelines</a></li>
</tr>
<tr>
<td class="answer"><input type="checkbox" name="ViewInstructions"
onClick="document.FormName.Instructions.value = 'Chronic kidney disease (CKD) describes abnormal kidney function and/or structure. It is common, frequently unrecognized and often exists together with other conditions (for example, cardiovascular disease and diabetes). When advanced, it also carries a higher risk of mortality. The risk of developing CKD increases with increasing age, and some conditions that coexist with CKD become more severe as kidney dysfunction advances. CKD can progress to established renal failure in a small but significant percentage of people.CKD is usually asymptomatic. But it is detectable, and tests for detecting CKD are both simple and freely available. There is evidence that treatment can prevent or delay the progression of CKD, reduce or prevent the development of complications and reduce the risk of cardiovascular disease. However, because of a lack of specific symptoms people with CKD are often not diagnosed, or diagnosed late when CKD is at an advanced stage.';
">What is CKD?</td>
<td class="answer"><input type="checkbox" name="ViewInstructions2"
onClick="document.FormName.Instructions.value = 'Treatment and care should take into account peoples needs and preferences. People with chronic kidney disease should have the opportunity to make informed decisions about their care and treatment, in partnership with their health care professionals.Good communication between health care professionals and patients is essential. It should be supported by evidence-based written information tailored to the persons needs. Treatment and care, and the information people are given about it, should be culturally appropriate.If the person agrees, families and carers should have the opportunity to be involved in decisions about treatment and care. Families and carers should also be given the information and support they need.';
">Treatment and care options:</td>
<td class="answer"><input type="checkbox" name="ViewInstructions3"
onClick="document.FormName.Instructions.value = 'Offer people testing for CKD if they have any of the following risk factors: \nDiabetes \nHypertension\n Cardiovascular disease (ischemic heart disease, chronic heart failure, peripheral vascular disease and cerebral vascular disease)\n Structural renal tract disease, renal calculi or prostatic hypertrophy\n Multisystem diseases with potential kidney involvement for example, systemic lupus erythematosus\n Family history of stage 5 CKD or hereditary kidney disease \nOpportunistic detection of hematuria or proteinuria.';
">Who should be offered screening for CKD?</td>
<td class="answer"><input type="checkbox" name="ViewInstructions4"
onClick="document.FormName.Instructions.value = 'The color code is as follows:\n For the value boxes, red - value is elevated, green-value in normal range, blue-value is reduced.\n An empty lilac box indicates the need to consider doing that test. Grey indicates test not indicated.\n For the date boxes, lilac-test is due, green- test is up to date, orange-test coming due in 3 months.\n If a value is entered in baseline eGFR, orange means the decline in eGFR is significant. ';
">Color code</td>
<table width="1000px">
<tr>
<td class="QuestionHeading" width=25%>Patient name</td>
<td class="formtext"><input class="formtext" name="PatientName" type="text" oscarDB=patient_name></td>
<td class="QuestionHeading">Date:</td>
<td class="formtext"><input class="formtext" name="TodaysDate" type="text" oscarDB=today></td>
</tr>
<tr>
<td class="QuestionHeading">Patients age:</td>
<td class="formtext"><input class="formtext" name="age" id="age" type="text" oscarDB=age></td>
<td class="QuestionHeading">Sex:</td>
<td class="formtext"><input class="formtext" name="Sex" id="Sex" type="text" oscarDB=sex></td>
<td ><input type="radio" name="GenderRadio" id ="Male" style="display:none;" value="1"></td>
<td ><input type="radio" name="GenderRadio" id="Female" style="display:none;" value="2"></td>
</tr>
</table>
<table width="1000px">
<tr>
<td class="QuestionHeading" width=25%>Ethnic origin</td>
<td class="answer" width=2.5%><input type="checkbox" name="ET1" id="ET1"></td>
<td class="question" width=10%><p class="normal" id="Aboriginal">Aboriginal</td>
<td class="answer" width=2.5%><input type="checkbox" name="ET2" id="ET2"></td>
<td class="question" width=10%><p class="normal" id="African">African</td>
<td class="answer" width=2.5%><input type="checkbox" name="ET3" id="ET3"></td>
<td class="question" width=10%><p class="normal" id="Asian">Asian</td>
<td class="answer" width=2.5%><input type="checkbox" name="ET4" id="ET4"></td>
<td class="question" width=10%><p class="normal" id="European">European</td>
<td class="answer" width=2.5%><input type="checkbox" name="ET5" id="ET5"></td>
<td class="question" width=10%><p class="normal" id="South Asian">South Asian</td>
<td class="answer" width=2.5%><input type="checkbox" name="ET6" id="ET6"></td>
<td class="question" width=10%><p class="normal" id="Other">Other</td>
</tr>
</table>
<br>
</div>
<div name="Results" >
<table width="1000px">
<tr>
<td class="AnswerHeading" width=3%></td>
<td class="QuestionHeading" width=47%>Existing medical conditions:</td>
<td class="AnswerHeading" width=50%></td>
</tr>
</table>
<table width="1000px">
<tr class="even">
<td class="answer" width=3%><input type="checkbox" name="E1" id="E1"></td>
<td class="question" width=7%><p class="normal" id="diabetes">Diabetes</td>
<td class="answer" width=3%><input type="checkbox" name="E2" id="E2"></td>
<td class="question" width=7%><p class="normal" id="hypertension">HBP</td>
<td class="answer" width=3%><input type="checkbox" name="E4" id="E4"></td>
<td class="question" width=7%><p class="normal" id="IHD">IHD</td>
<td class="answer" width=3%><input type="checkbox" name="E5" id="E5"></td>
<td class="question" width=7%><p class="normal" id="CVD">CVD</td>
<td class="answer" width=3%><input type="checkbox" name="E3" id="E3"></td>
<td class="question" width=17%><p class="normal" id="structural">Structural Renal Disease</td>
<td class="answer" width=3%><input type="checkbox" name="E6" id="E6"></td>
<td class="question" width=17%><p class="normal" id="hematuria">Persistent hematuria</td>
<td class="answer" width=3%><input type="checkbox" name="E7" id="E7"></td>
<td class="question" width=17%><p class="normal" id="FH">FH polycystic kidney disease </td>
</tr>
</table>
</div>
<div name="Questionnaire" >
<table width="1000px">
<tr>
<td class="AnswerHeading" width=3%></td>
<td class="QuestionHeading" width=47%>Laboratory data:</td>
<td class="AnswerHeading" width=50%></td
</tr>
</table>
<table width="1000">
<tr class="assessment">
<td class="question"width = "1%"><p class="normal" id="BMI">BMI</p></td>
<td class="answer"width = "2%"><input type="checkbox" name="BMI1" id="BMI1"
onClick="document.FormName.Instructions.value = 'BMI: Normal range 18.5-25. ';"></td>
<td class="formtext"width="6%"><input class="formtext" name="BMI2" id="BMI2" type="text" oscarDB=m$BMI#value></td>
<td class="formtext"width="6%"><input class="formtext2" name="BMI3" id="BMI3" type="text" oscarDB=m$BMI#dateObserved></td>
<td class="question"width = "1%"><p class="normal" id="BP">BP</p></td>
<td class="answer"width = "2%"><input type="checkbox" name="BP1" id="BP1"
onClick="document.FormName.Instructions.value = 'In people with CKD aim to keep the systolic blood pressure below 140 mmHg (target range 120 to 139 mmHg) and the diastolic blood pressure below 90 mmHg .\n In people with CKD and diabetes, and also in people with an ACR 70 mg/mmol or more (approximately equivalent to urinary protein excretion 1 g/24 h or more) aim to keep the systolic blood pressure below 130 mmHg (target range 120 to 129 mmHg) and the diastolic blood pressure below 80 mmHg.';"></td>
<td class="formtext"width="6%"><input class="bdr" size="5" name="BP2" id="BP2" onchange="Update() type="text"</td>
<td class="formtext"width="6%"><input class="formtext2" name="BP3" id="BP3" type="text" oscarDB=m$BP#dateObserved></td>
<td class="question"width = "1%"><p class="normal" id="Alb">Albumin</p></td>
<td class="answer"width = "2%"><input type="checkbox" name="Alb1" id="Alb1"
onClick="document.FormName.Instructions.value = 'Albumin: Normal range 35-50.';"></td>
<td class="formtext"width="6%"><input class="formtext" name="Alb2" id="Alb2" type="text" oscarDB=m$Alb#value></td>
<td class="formtext"width="6%"><input class="formtext2" name="Alb3" id="Alb3" type="text" oscarDB=m$Alb#dateObserved></td>
<td class="question"width = "1%"><p class="normal" id="Ca">Ca</p></td>
<td class="answer"width = "2%"><input type="checkbox" name="Ca1" id="Ca1"
onClick="document.FormName.Instructions.value = 'Ca: Normal range 2.10-2.60';"></td>
<td class="formtext"width="6%"><input class="formtext" name="Ca2" id="Ca2" type="text" oscarDB=m$Ca#value></td>
<td class="formtext"width="6%"><input class="formtext2" name="Ca3" id="Ca3" type="text" oscarDB=m$Ca#dateObserved></td>
<td class="question"width = "1%"><p class="normal" id="PO4">PO4</p></td>
<td class="answer"width = "2%"><input type="checkbox" name="PO41" id="PO41"
onClick="document.FormName.Instructions.value = 'Phosphorus: Normal range 0.8-1.5\n In CKD aim to keep below 1.8.';"></td>
<td class="formtext"width="6%"><input class="formtext" name="PO42" id="PO42" type="text" oscarDB=m$Phos#value></td>
<td class="formtext"width="6%"><input class="formtext2" name="PO43" id="PO43" type="text" oscarDB=m$Phos#dateObserved></td>
<td class="question"width = "1%"><p class="normal" id="iPTH">iPTH</p></td>
<td class="answer"width = "2%"><input type="checkbox" name="iPTH1" id="iPTH1"
onClick="document.FormName.Instructions.value = 'iPTH: Normal range 0.5-12.0.\n In CKD aim to keep below 2-3 times normal depending on the eGFR.';"></td>
<td class="formtext"width="6%"><input class="formtext" name="iPTH2" id="iPTH2" type="text" oscarDB=m$iPTH#value></td>
<td class="formtext"width="6%"><input class="formtext2" name="iPTH3" id="iPTH3" type="text" oscarDB=m$iPTH#dateObserved></td>
</tr>
<tr class="assessment">
<td class="question"width = "1%"><p class="normal" id="eGFR8">eGFR</p></td>
<td class="answer"width = "2%"><input type="checkbox" name="eGFR4" id="eGFR4"
onClick="document.FormName.Instructions.value = 'Interpret reported values of eGFR 60 or more with caution, bearing in mind that estimates of GFR become less accurate as the true GFR increases.\nWhere eGFR is simply reported as 60 or more, use a rise in serum creatinine concentration of more than 20% to infer significant reduction in renal function. \n In cases where there are extremes of muscle mass, for example, in bodybuilders, amputees or people with muscle wasting disorders, interpret the eGFR with caution. (Reduced muscle mass will lead to overestimation and increased muscle mass to underestimation of the GFR.)\nAdvise people not to eat any meat in the 12 hours before having a blood test for GFR estimation. Avoid delaying the dispatch of blood samples to ensure that they are received and processed by the laboratory within 12 hours of venepuncture.\n An eGFR result less than 60 in a person not previously tested should be confirmed by repeating the test within 2 weeks. Make an allowance for biological and analytical variability of serum creatinine (approx 5%) when interpreting changes in eGFR'"></td>
<td class="formtext"width="6%"><input class="formtext" name="eGFR5" id="eGFR5" type="text" oscarDB=m$EGFR#value></td>
<td class="formtext"width="6%"><input class="formtext2" name="eGFR7" id="eGFR7" type="text" oscarDB=m$EGFR#dateObserved></td>
<td class="question"width = "1%"><p class="normal" id="ACR">ACR</p></td>
<td class="answer"width = "2%"><input type="checkbox" name="ACR1" id="ACR1"
onClick="document.FormName.Instructions.value = 'In people without diabetes consider clinically significant proteinuria to be present when the ACR is 30 mg/mmol or more (this is approximately equivalent to PCR 50 mg/mmol or more, or a urinary protein excretion 0.5 g/24 h or more).\n In people with diabetes consider microalbuminuria (ACR more than 2.5 mg/mmol in men and ACR more than 3.5 mg/mmol in women) to be clinically significant.\n All people with diabetes, and people without diabetes with a GFR less than 60 , should have their urinary albumin/protein excretion quantified. The first abnormal result should be confirmed on an early morning sample (if not previously obtained).';"></td>
<td class="formtext"width="6%"><input class="formtext" name="ACR2" id="ACR2" type="text" oscarDB=m$ACR#value></td>
<td class="formtext"width="6%"><input class="formtext2" name="ACR3" id="ACR3" type="text" oscarDB=m$ACR#dateObserved></td>
<td class="question"width = "1%"><p class="normal" id="Hb">Hb</p></td>
<td class="answer"width = "2%"><input type="checkbox" name="Hb1" id="Hb1"
onClick="document.FormName.Instructions.value = 'Hb: Normal range in females 115-160\nNormal range in males 135-180';"></td>
<td class="formtext"width="6%"><input class="formtext" name="Hb2" id="Hb2" type="text" oscarDB=m$Hb#value></td>
<td class="formtext"width="6%"><input class="formtext2" name="Hb3" id="Hb3" type="text" oscarDB=m$Hb#dateObserved></td>
<td class="question"width = "1%"><p class="normal" id="TSAT">TSAT</p></td>
<td class="answer"width = "2%"><input type="checkbox" name="TSAT1" id="TSAT1"
onClick="document.FormName.Instructions.value = 'Transferrin saturation: Normal range 0.15-0.55.\n In CKD aim to keep >0.20.\n >0.45 needs investigation for potential iron overload.';"></td>
<td class="formtext"width="6%"><input class="formtext" name="TSAT2" id="TSAT2" type="text" oscarDB=m$TSAT#value></td>
<td class="formtext"width="6%"><input class="formtext2" name="TSAT3" id="TSAT3" type="text"oscarDB=m$TSAT#dateObserved></td>
<td class="question"width = "1%"><p class="normal" id="LDL">LDL</p></td>
<td class="answer"width = "2%"><input type="checkbox" name="LDL1" id="LDL1"
onClick="document.FormName.Instructions.value = 'LDL: Normal adult range 1.5-3.4';"></td>
<td class="formtext"width="6%"><input class="formtext" name="LDL2" id="LDL2" type="text" oscarDB=m$LDL#value></td>
<td class="formtext"width="6%"><input class="formtext2" name="LDL3" id="LDL3" type="text" oscarDB=m$LDL#dateObserved></td>
<td class="question"width = "1%"><p class="normal" id="A1C">A1C</p></td>
<td class="answer"width = "2%"><input type="checkbox" name="A1C1" id="A1C1"
onClick="document.FormName.Instructions.value = 'HbA1C: Normal range 4.8-6.2.';"></td>
<td class="formtext"width="6%"><input class="formtext" name="A1C2" id="A1C2" type="text" oscarDB=m$A1C#value></td>
<td class="formtext"width="6%"><input class="formtext2" name="A1C3" id="A1C3" type="text" oscarDB=m$A1C#dateObserved></td>
</tr>
<tr class="assessment">
<td class="question"width = "1%"><p class="normal" id="eGFR">BaseGFR</p></td>
<td class="answer"width = "2%"><input type="checkbox" name="eGFR1" id="eGFR1"
onClick="document.FormName.Instructions.value = 'Interpret reported values of eGFR 60 or more with caution, bearing in mind that estimates of GFR become less accurate as the true GFR increases.\nWhere eGFR is simply reported as 60 or more, use a rise in serum creatinine concentration of more than 20% to infer significant reduction in renal function. \n In cases where there are extremes of muscle mass, for example, in bodybuilders, amputees or people with muscle wasting disorders, interpret the eGFR with caution. (Reduced muscle mass will lead to overestimation and increased muscle mass to underestimation of the GFR.)\nAdvise people not to eat any meat in the 12 hours before having a blood test for GFR estimation. Avoid delaying the dispatch of blood samples to ensure that they are received and processed by the laboratory within 12 hours of venepuncture.\n An eGFR result less than 60 in a person not previously tested should be confirmed by repeating the test within 2 weeks. Make an allowance for biological and analytical variability of serum creatinine (approx 5%) when interpreting changes in eGFR'"></td>
<td class="formtext"width="6%"><input class="formtext3" name="eGFR2" id="eGFR2" type="text" oscarDB=m$BGFR#value></td>
<td class="formtext"width="6%"><input class="formtext2" name="eGFR3" id="eGFR3" type="text" oscarDB=m$BGFR#dateObserved></td>
</tr>
</table>
<table>
<tr>
<td><input type="button" onclick="totalScore(),date()" value="CKD stage:"></td>
<td><input value="Reset Advisor" name="ResetButton" type="reset"></td>
</tr>
</table>
</div>
<div name="Results" >
<table width="1000px">
<tr>
<td class="AnswerHeading" width=3%></td>
<td class="QuestionHeading" width=7%>CKD Stage:</td>
<td class="AnswerHeading" width=45%>Presentation</td>
<td class="AnswerHeading" width=45%>Suggested ongoing monitoring</td>
</tr>
<tr id="0" class="even">
<td class="answer"><input type="checkbox" name="S0" id="S0"
onClick="document.FormName.Instructions.value = 'Offer people testing for CKD if they have any of the following risk factors: \nDiabetes \nHypertension\n Cardiovascular disease (ischemic heart disease, chronic heart failure, peripheral vascular disease and cerebral vascular disease)\n Structural renal tract disease, renal calculi or prostatic hypertrophy\n Multisystem diseases with potential kidney involvement for example, systemic lupus erythematosus\n Family history of stage 5 CKD or hereditary kidney disease \nOpportunistic detection of hematuria or proteinuria.';"></td>
<td class="question1"><p class="normal" >At Risk</td>
<td class="answer">At higher risk include those with Diabetes,Hypertension,FH of CKD,Ethnic</td>
<td class="answer">eGFR/ACR Q12-24M</td>
</tr>
<tr id="1" class="even">
<td class="answer"><input type="checkbox" name="S1" id="S1"
onClick="document.FormName.Instructions.value = 'Stage 1 CKD is kidney damage with normal GFR (>90). \nKidney damage is seen in abnormalities in blood or urine or imaging studies\n For example: proteinuria or hematuria, a genetic diagnosis of kidney disease (e.g. polycystic kidney disease), evidence of structurally abnormal kidneys (e.g. reflux nephropathy, renal dysgenesis).\nThe aim is to identify individuals at risk of progressive renal disease, and reduce associated risks.\nRisk of cardiovascular events and death is substantially increased by the presence of CKD; at CKD 1-2, particularly by proteinuria.\n The risk of cardiovascular death is (on average) much higher than the risk of needing dialysis or a renal transplant.\nInvestigate those patients further where there are pointers to progression of renal disease eg:\proteinuria when ACR>70, hematuria of renal origin, declining eGFR or young age.\n Suggested monitoring: Annual creatinine/ eGFR / ACR / BP/ Cardiovascular risk assessment';"></td>
<td class="question1"><p class="normal" >Stage 1</td>
<td class="answer">Normal renal function with evidence of kidney disease</td>
<td class="answer">eGFR/ACR Q12M</td>
</tr>
<tr id="2" class="even">
<td class="answer"><input type="checkbox" name="S2" id="S2"
onClick="document.FormName.Instructions.value = 'Stage 2 CKD is mild reduction in GFR (60-89 ) with kidney damage.\nKidney damage is seen in abnormalities in blood or urine or imaging studies\n For example: proteinuria or hematuria, a genetic diagnosis of kidney disease (e.g. polycystic kidney disease), evidence of structurally abnormal kidneys (e.g. reflux nephropathy, renal dysgenesis).\nThe aim is to identify individuals at risk of progressive renal disease, and reduce associated risks.\nRisk of cardiovascular events and death is substantially increased by the presence of CKD; at CKD 1-2, particularly by proteinuria.\n The risk of cardiovascular death is (on average) much higher than the risk of needing dialysis or a renal transplant.\nInvestigate those patients further where there are pointers to progression of renal disease eg:\proteinuria when ACR>70, hematuria of renal origin, declining eGFR or young age.\n Suggested monitoring: Annual creatinine/ eGFR / ACR / BP/ Cardiovascular risk assessment';"></td>
<td class="question1"><p class="normal">Stage 2</td>
<td class="answer">Mildly reduced renal function (eGFR 60-89) with evidence of kidney disease</td>
<td class="answer">eGFR/ACR Q12M</td>
</tr>
<tr id="3" class="even">
<td class="answer"><input type="checkbox" name="S3" id="S3"
onClick="document.FormName.Instructions.value = 'Stage 3 CKD is moderate reduction in GFR (30-59).\n Approach: Clinical assessment for sepsis, heart failure, hypovolaemia, examination for bladder enlargement.\n Urine testing for ACR/ haematuria.\n Imaging to exclude urinary obstruction.\nSuggested ongoing monitoring: Q6 then 12 monthly Creatinine, K, Hb, ACR, Blood pressure, Cardiovascular risk assessment, Immunization (influenza and pneumococcal), Regular medication review.';"></td>
<td class="question1"><p class="normal">Stage 3</td>
<td class="answer">Moderately reduced renal function:(eGFR 30-59) (eGFR 45-59(3A) or 30-44(3B))</td>
<td class="answer">eGFR/ACR Q6M: Consider Hb/Ca/Alb/PO4/iPTH/Transferrin Sat Q12M</td>
</tr>
<tr id="4" class="even">
<td class="answer"><input type="checkbox" name="S4" id="S4"
onClick="document.FormName.Instructions.value = 'Stage 4 CKD is severe reduction in eGFR (15-29 ). Preparation for renal replacement therapy.\n Approach: Clinical assessment for sepsis, heart failure, hypovolaemia, examination for bladder enlargement , cardiovascular system.\n Medication review for nephrotoxic drugs, or drugs that need dose alterations when eGFR is reduced.\n Urine tests: dipstick for blood and quantitation of proteinuria by ACR. Presence of haematuria or proteinuria may suggest progressive renal disease.\n Blood tests: Ca, PO4, Hb. Imaging to exclude obstruction by US.\n Referral to a specialist is advisable.\nTypically 3 monthly estimation of: Creatinine, K, Hb, Ca ,phosphate, ACR, BP, Cardiovascular risk assessment, Medication review (to avoid nephrotoxic drugs and ensure appropriate dosages)\nAnnual influenza immunisation, appropriate pneumococcal immunisation plus hepatitis B immunization if renal replacement therapy contemplated.';"></td>
<td class="question1"><p class="normal">Stage 4</td>
<td class="answer">Severely reduced renal function (eGFR 15-29)</td>
<td class="answer">As per nephrologist</td>
</tr>
<tr id="5" class="even">
<td class="answer"><input type="checkbox" name="S5" id="S5"
onClick="document.FormName.Instructions.value = 'Stage 5 CKD is established kidney failure (GFR <15) requiring renal replacement therapy.\nApproach: Clinical assessment for sepsis, heart failure, hypovolaemia, examination for bladder enlargement , cardiovascular system.\n Medication review for nephrotoxic drugs, or drugs that need dose alterations when eGFR is reduced.\n Urine tests: dipstick for blood and quantitation of proteinuria by ACR. Presence of haematuria or proteinuria may suggest progressive renal disease.\n Blood tests: Ca, PO4, Hb. Imaging to exclude obstruction by US.\n Referral to a specialist is advisable.\nTypically 3 monthly estimation of: Creatinine, K, Hb, Ca ,phosphate, ACR, BP, Cardiovascular risk assessment, Medication review (to avoid nephrotoxic drugs and ensure appropriate dosages)\nAnnual influenza immunisation, appropriate pneumococcal immunisation plus hepatitis B immunization if renal replacement therapy contemplated.';"></td>
<td class="question1"><p class="normal">Stage 5</td>
<td class="answer">Very severely reduced renal function (Endstage) (eGFR < 15)</td>
<td class="answer">As per nephrologist</td>
</tr>
</table>
<table width="1000">
<tr>
<td width="1000"><textarea name="Instructions" id="Instructions" style="background-color: #b0c4de; border: 1px solid #000000;font-weight: bold; font-family: Arial; font-size: 12px; width:1000; height: 150px" ></textarea></td>
</tr>
</table>
<table width="1000px">
<tr>
<td class="AnswerHeading" width=3%></td>
<td class="QuestionHeading" width=47%>Management options:</td>
<td class="AnswerHeading" width=50%></td>
</tr>
<table>
<table width="1000px">
<tr class="even">
<td class="answer"width=3%><input type="checkbox" name="M1" id="M1"
onClick="document.FormName.Instructions.value = 'Consider recommending exercise, weight loss, smoking cessation, healthy eating habits.';"></td>
<td class="question"width=46%><p class="normal" id = "lifestyle" name = "lifestyle">Lifestyle changes and risk factor modification</p></td>
<td class="question" width=12.5%><p class="normal" id = "RDM" name = "RDM"> Diabetes </p></td>
<td class="question" width=12.5%><p class="normal" id = "RHBP" name = "RHBP"> Hypertension</p></td>
<td class="question" width=12.5%><p class="normal" id = "RBMI" name = "RBMI"> BMI > 25 </p></td>
<td class="question" width=12.5%><p class="normal" id = "RLDL" name = "RLDL"> LDL > 2.4 </p></td>
<tr>
</table>
<table width="1000px">
<tr class="even">
<td class="answer"width=3%><input type="checkbox" name="M6" id="M6"
onClick="document.FormName.Instructions.value = 'Management of anaemia should be considered in CKD with haemoglobin (Hb) level is less than or equal to 110 (or 100 if < 2 years ). \nTreatment with EPO should be offered to people who are likely to benefit in terms of quality of life and physical function.\n An eGFR of less than 60 should trigger investigation into whether anaemia is due to CKD. When the eGFR is > 60 the anaemia is more likely from other causes. \n Iron-deficiency anaemia is confirmed by a transferrin saturation less than 20%.\nPeople with anaemia of CKD who are receiving EPO should be given iron therapy to maintain a transferrin saturation greater than 20%.\n Most patients will require 150 to 200 mg of elemental iron for adults or equivalent doses for children, in a single or divided dose depending on the preparation.\n Ferrous fumerate: 106mg elemental iron/tablet, Ferrous sulphate 65mg /tablet, Ferrous gluconate 28-36mg /tablet, Ferrous sulphate elixir 44mg/5ml.\n Do not use enteric coated or slow release preparations. Addition of Vit C with each dose is helpful.\n Those patients who do not respond to oral iron will require intravenous iron.\n ';"></td>
<td class="question"width=47%><p class="normal" id = "MFe" name = "MFe">Consider iron supplementation</p></td>
<td class="question"width=25%><p class="normal" id = "Hb110" name = "Hb110">Hb < 110 </p> </td>
<td class="question"width=25%><p class="normal" id = "TSAT0.2" name = "TSAT0.2">TSAT < 0.2 </p> </td>
<tr>
<tr class="even">
<td class="answer"><input type="checkbox" name="M4" id="M4"
onClick="document.FormName.Instructions.value = 'Refer to dietician';"></td>
<td class="question"><p class="normal" id = "MPO4" name = "MPO4">Consider reducing phosphate in diet</p></td>
<td class="question"><p class="normal" id = "PO41.5" name = "PO41.5">PO4 > 1.5 </p></td>
<td class="question"><p class="normal"></p></td>
<tr>
</table>
<table width="1000px">
<tr class="even">
<td class="answer"width=3%><input type="checkbox" name="M5" id="M5"
onClick="document.FormName.Instructions.value = 'Dosage range 1000-2000mg elemental calcium per day.\nCaCO3 is 40% elemental, needs to be taken with meals and is affected by PPI and H2 blockers. CaCO3(Tums) 1000mg tid = 400mg tid elemental= 1200mg elemental/day\nCa Citrate is 20% elemental and can be taken without food and with PPI/H2 blockers. Ca Citrate tablets 200mg or 250mg elemental. 2 tabs tid = 1200mg-1500mg elemental/day.\nCa Acetate is 25% elemental.\nCalcium carbonate is cheapest and therefore often a good first choice unless circumstances require Ca Citrate\nCa supplementation > 500mg elemental should be in divided doses.\nCalcium supplements interfere with the absorption of iron and thyroid hormone, therefore these medications should be taken at different times.';"></td>
<td class="question"width=47%><p class="normal" id = "MCa" name = "MCa">Consider adding calcium supplementation</p></td>
<td class="question" width=25%><p class="normal" id = "CaValue" name = "CaValue">Serum Ca < 2.1</td>
<td class="question" width=25%><p class="normal" id = "PO4Value" name = "PO4Value">Serum PO4 > 1.5</td>
<tr>
</table>
<table width="1000px">
<tr class="even">
<td class="answer" width=3%><input type="checkbox" name="M12" id="M12"
onClick="document.FormName.Instructions.value = 'When vitamin D supplementation is indicated in people with CKD offer:\n Cholecalciferol (D3) or ergocalciferol(D2) to people with stage 1-3 CKD: Vit D3 1000iu daily po\n 1-alpha-hydroxycholecalciferol (alfacalcidol) or 1,25-dihydroxycholecalciferol (calcitriol) to people with stage 3-5 CKD: One-Alpha 0.25mcg-1mcg starting three times per week (MWF) and gradually increasing to daily based on response. \nMonitor serum calcium and phosphate concentrations in people receiving 1-alpha-hydroxycholecalciferol or 1,25-dihydroxycholecalciferol supplementation Q3 months.\n (Aim phosphate normal and Ca <2.37).';"></td>
<td class="question" width=45%><p class="normal" id = "MD" name = "MD">Consider adding Vit D to reach a target iPTH based on the kidney stage</p></td>
<td class="question" width=16.7%><p class="normal" id = "MS3" name = "MS3"> Stage 3 iPTH 3.8-7.7 </p></td>
<td class="question" width=16.7%><p class="normal" id = "MS4" name = "MS4"> Stage 4 iPTH 7.7-12</p></td>
<td class="question" width=16.7%><p class="normal" id = "MS5" name = "MS5"> Stage 5 iPTH 16.5-33</p></td>
<tr>
</table>
<table width="1000px">
<tr class="even">
<td class="answer" width=3%><input type="checkbox" name="M2" id="M2"
onClick="document.FormName.Instructions.value = 'Offer ACE inhibitors/ARBs to people with diabetes and ACR more than 2.5 mg/mmol (men) or more than 3.5 mg/mmol (women) irrespective of the presence of hypertension or CKD stage .\n Offer ACE inhibitors/ARBs to non-diabetic people with CKD and hypertension and ACR 30 mg/mmol or more (approximately equivalent to urinary protein excretion 0.5 g/24 h or more).\n Offer ACE inhibitors/ARBs to non-diabetic people with CKD and ACR 70 mg/mmol or more (approximately equivalent to PCR 100 mg/mmol or more, or urinary protein excretion 1 g/24 h or more) irrespective of the presence of hypertension or cardiovascular disease. \nOffer non-diabetic people with CKD and hypertension and ACR less than 30 mg/mmol (approximately equivalent to urinary protein excretion less than 0.5 g/24 h) a choice of antihypertensive treatment to prevent or ameliorate progression of CKD.\n When using ACE inhibitors/ARBs titrate them to the maximum tolerated therapeutic dose before adding a second-line agent.';"></td>
<td class="question" width=47%><p class="normal" id = "MBP" name = "MBP">Consider improving blood pressure control: Target</p></td>
<td class="question" width=25%><p class="normal" id = "minus" name = "minus"> <140/90 </p></td>
<td class="question" width=25%><p class="normal" id = "plus" name = "plus">< 130/80 if proteinuria (ACR>30)</p></td>
<tr>
</table>
<table width="1000px">
<tr class="even">
<td class="answer"width=3%><input type="checkbox" name="M3" id="M3"
onClick="document.FormName.Instructions.value = 'In CKD, measure K and eGFR before starting ACEi/ARB. Repeat these measurements between 1 and 2 weeks after starting and after each dose increase.\nACEi/ARB therapy should not be started if the pretreatment K > 5.0.\n Concurrent prescription of drugs increasing K is OK but monitor more frequently.\nStop ACEi/ARB therapy if the K rises to 6.0.\nFollowing the start or increase of ACEi/ARB, GFR decrease less than 25% or creatinine increase less than 30% is OK.\nIf the change in eGFR is > 25% or the change in creatinine is > 30%, look for other causes such as volume depletion or concurrent medication (for example, NSAIDs). If no other cause for the deterioration is found, stop the ACEi/ARB therapy or reduce the dose, and add an alternative antihypertensive medication if required.\n Where indicated, the use of ACEi/ARBs should not be influenced by a persons age as there is no evidence that their appropriate use in older people is associated with a greater risk of adverse effects.';"></td>
<td class="question"width=45%><p class="normal" id = "ACE" name = "ACE">Consider ACEi or ARB</p></td>
<td class="question" width=16.7%><p class="normal" id = "DMACR" name = "DMACR">DM + ACR >1.9/2.7</td>
<td class="question" width=16.7%><p class="normal" id = "HBPACR" name = "HBPACR">HBP + ACR >29</td>
<td class="question" width=16.7%><p class="normal" id = "NACR" name = "NACR">ACR > 69</td>
<tr>
</table>
<table width="1000px">
<tr>
<td class="AnswerHeading" width=3%></td>
<td class="QuestionHeading" width=47%>Other strategies:</td>
<td class="AnswerHeading" width=50%></td>
</tr>
<tr class="even">
<td class="answer"><input type="checkbox" name="M8" id="M8"
onClick="document.FormName.Instructions.value = 'Infectious disease is the second most common cause of death in late-stage chronic kidney disease (CKD) patients (first being cardiovascular causes).\nAlthough CKD patients are immunocompromised, some vaccines such as influenza, retain their efficacy and reduce infection rates with a standard immunization schedule. \nOther vaccines, such as hepatitis B and pneumococcal vaccines, require more frequent and/or higher doses to produce and maintain protective antibody levels.\nCenters with vaccination protocols have demonstrated reduced infection rates and resultant decreased morbidity and mortality. \n It could be extrapolated from this that widespread vaccination would reduce the total cost of ESRD patient care, and potentially improve patient well-being. \n However, vaccination appears to be underutilized in CKD patients, and it is a readily available intervention to improve outcomes.';"></td>
<td class="question" bgcolor="yellow"><p class="normal" id = "influenza" name = "influenza" >Encourage annual influenza vaccination and check pneumococcal vaccination status </p></td>
<td class="answer"></td>
</tr>
</table>
<table width="1000px">
<tr class="even">
<td class="answer" width=3%><input type="checkbox" name="M10" id="M10"
onClick="document.FormName.Instructions.value = 'Offer a renal ultrasound to all people with CKD who:\n Have progressive CKD (eGFR decline more than 5 ml/min/1.73 m2 within 1 year, or more than 10 ml/min/1.73 m2 within 5 years)\n Have gross or persistent microscopic haematuria\nHave symptoms of urinary tract obstruction\nHave a family history of polycystic kidney disease and are aged over 20 \nHave stage 4 or 5 CKD \n Are considered by a nephrologist to require a renal biopsy.\n Advise people with a family history of inherited kidney disease about the implications of an abnormal result before a renal ultrasound scan is arranged for them.';"></td>
<td class="question" width=46%><p class="normal" id = "US" name = "US">Consider renal US</p></td>
<td class="answer" width=12.5%><p class="normal"id = "US1" name = "US1">eGFR<30</p></td>
<td class="answer" width=12.5%><p class="normal"id = "US2" name = "US2">FH Polycystic KD</p></td>
<td class="answer" width=12.5%><p class="normal"id = "US3" name = "US3">Persistent hematuria</p></td>
<td class="answer" width=12.5%><p class="normal"id = "US4" name = "US4">Declining eGFR</p></td>
</tr>
<tr class="even">
<td class="answer"><input type="checkbox" name="M11" id="M11"
onClick="document.FormName.Instructions.value = 'People with CKD in the following groups should normally be considered for referral for specialist assessment:\n Stage 4 and 5 CKD (with or without diabetes)\n Higher levels of proteinuria (ACR 70 mg/mmol or more, approximately equivalent to urinary protein excretion 1 g/24 h or more) unless known to be due to diabetes and already appropriately treated\n Proteinuria (ACR 30 mg/mmol or more, approximately equivalent to urinary protein excretion 0.5 g/24 h or more) together with haematuria\n Rapidly declining eGFR (more than 5 ml/min/1.73 m2 in 1 year, or more than 10 ml/min/1.73 m2 within 5 years)\n Hypertension that remains poorly controlled despite the use of at least four antihypertensive drugs at therapeutic doses \n People with, or suspected of having, rare or genetic causes of CKD\n Suspected renal artery stenosis.';"></td>
<td class="question"><p class="normal" id = "refer" name = "refer">Consider referring for nephrology consultation</p></td>
<td class="answer" ><p class="normal" id = "refer1" name = "refer1">eGFR<30</p></td>
<td class="answer" ><p class="normal" id = "refer2" name = "refer2">ACR>69</p></td>
<td class="answer" ><p class="normal" id = "refer3" name = "refer3">ACR>29+hematuria</p></td>
<td class="answer" ><p class="normal" id = "refer4" name = "refer4">Declining eGFR</p></td>
</tr>
</table>
<table width="1000px">
<tr class="even">
<td class="answer" width=3%><input type="checkbox" name="M12" id="M12"
onClick="document.FormName.Instructions.value = 'The use of statin therapy for the primary prevention of cardiovascular disease (CVD),in people with CKD should not differ from its use in people without CKD and should be based on existing risk tables for people with and without diabetes.\n It should be understood that the Framingham risk tables significantly underestimate risk in people with CKD.\nOffer statins to people with CKD for the secondary prevention of CVD irrespective of baseline lipid values.\nOffer antiplatelet drugs to people with CKD for the secondary prevention of CVD.\n CKD is not a contraindication to the use of low dose aspirin but clinicians should be aware of the increased risk of minor bleeding in people with CKD given multiple antiplatelet drugs.\n There is insufficient evidence to recommend the routine use of drugs to lower uric acid in people with CKD who have asymptomatic hyperuricaemia.';"></td>
<td class="question" width=47%><p class="normal" id = "statin" name = "refer">Statin and antiplatelet use</p></td>
<td class="answer" width=50%></td>
</tr>
</table>
<table width="1000px">
<tr class="even">
<td class="answer" width=3%><input type="checkbox" name="M13" id="M13"
onClick="document.FormName.Instructions.value = 'Test for iron overload using a fasting transferring saturation (fTS). If fTS < 0.45, no further testing is required.If fTS is between 0.45 and 0.60, repeat test within a month.\nIf repeat test is < 0.45, no further hemochromatosis testing is required.If repeat test is > 0.45, do DNA testing for HFE mutations.\nSerum ferritin is not a reliable screening test for iron overload because it may be elevated for other reasons.\n Once iron overload is diagnosed or if a hereditary cause of hemochromatosis is confirmed, ferritin levels should be brought down to <50 ng/ml by weekly phlebotomy then a maintenance schedule followed.\nIf DNA testing confirms the presence of two HFE mutations, at least one of which is C282Y and serum ferritin is normal, then monitor as follows:\nC282Y/C282Y - homozygotes: Monitor serum ferritin every two years.\nC282Y/H63D - compound heterozygotes: Less than three per cent will develop iron overload. Monitor ferritin every five years.\nC282Y/Norm - simple heterozygotes: Low risk of developing iron overload. Further ferritin testing is not required.\nFor ALL of the above, DNA testing should be offered to all first-degree relatives.\nIf iron overload is present, but DNA testing does not reveal the cause, then referral to a specialist is appropriate. ';"></td>
<td class="question" width=47%><p class="normal" id = "FeOverload" name = "FeOverload">Consider investigating for iron overload:</p></td>
<td class="question" width=25%><p class="normal" id = "TsatValue" name = "TsatValue"> TSAT > 0.45 </p></td>
<td class="question" width=25%><p class="normal"> <a href=" http://www.bcguidelines.ca/gpac/guideline_iron_overload.html" target="_blank">Iron Overload Guidelines</a> </p></td>
<tr>
</table>
<br>
</div>
<!-- The submit/print/reset buttons ------------------------------------------------------------->
<div name="FunctionButtons" class="DoNotPrint">
<table>
<tr>
<td class="subjectline">
Subject: <input name="subject" size="40" type="text">
<input value="Submit" name="SubmitButton" type="submit">
<input value="Reset" name="ResetButton" type="reset">
<input value="Print" name="PrintButton" onclick="javascript:window.print()" type="button">
<input type=button value="Close Window" onClick="javascript:window.close();" tabindex = "1">
</td>
</tr>
</table>
</div>
</form>
</body>
</html>
